ClinicalTrials.gg
Status unknownNCT03848377Updated Mar 6, 2019

EMG and SSEP Device (EPAD® 2.0) for Intraoperative Monitoring of Patient Undergoing Spinal Nerve Spine Surgery

An observational study in Spine Disease and Neurological Disorder, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Observational

The sponsor has not verified this record recently (last verified Mar 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

In patients undergoing spine surgery, spinal nerve roots and spinal cord are vulnerable to surgical insults especially for instrumentation and may lead to long term sequelae. The incidence of clinical peripheral neuropathy after cervical spine surgery has been reported up to 30%. Intraoperatively, spinal cord and nerves function can be monitored using electromyography (EMG) and somatosensory evoked potentials (SSEP) and thereby, intervention can be made to potentially reduce the incidence of adverse neurological sequelae. However, conventional EMG and SSEP monitoring requires presence of a trained EP technician, use of needle electrodes and currently bulky EP equipment and is thus not practical for routine clinical usage. In this study, the invesitgators will assess the clinical feasibility of using a novel miniaturized and automated EMG/SSEP device (EPAD® 2.0) in spine surgical patients.

Read the detailed description

Purpose of Research: This study is a pilot study designed to assess the ability of a novel automated EMG/SSEP device (EPAD® 2.0) to detect intraoperative spinal nerve roots injury in patients undergoing spine procedures. The specific aims are:

  1. to assess the clinical utility of using the EPAD® 2.0 automated device and its algorithm in monitoring spine surgery patients.
  2. to identify any practical limitation of using EPAD® 2.0 automated device in spine surgery patients.

Hypothesis: the novel automated EPAD® 2.0 EMG/SSEP device is easy to use and apply in spine surgery patients

BACKGROUND Surgical injuries to the spinal nerve roots or spinal cords are not infrequent in spine surgery and the consequence can be devastating. Injured patients might present with radiculopathy, motor weakness, spinal cord compression, and postoperative neuropathic pain. In cervical spine surgery, cervical nerve roots injuries especially fifth cervical (C5) nerve root are not uncommon complications, potentially resulting in upper extremity paralysis. The incidence of C5 nerve root injury ranged to as high as 30%. The other spinal nerve roots (C6-8) can suffer from the same surgical injuries during the procedure but with much lower reported incidence than C5. Spinal nerve injuries typically occur during decompression for cervical myelopathy in both anterior and posterior approaches. In lumbosacral spine surgery, a recent review of the neurological injury found a pooled incidence of 5.7% (56 of 2783 patients; range: 0.46-24%), in which pedicle malposition accounted for one-fifth of the injuries.

A multimodality monitoring such as SSEP and EMG can be used in spine surgery to allow comprehensive monitoring of the spinal cord and nerve roots function and an attempt to reduce the risks of surgical injuries. Although the idea of closely monitoring of spinal cord and nerve roots function during high-risk cervical spine instrumentation procedure is appealing, the utilization of intraoperative neurophysiological monitoring is limited. One reason is the current requirements for a trained technician and for electrode placement and observation of monitoring SSSEP signals, the requirement for the use of needle electrodes for SSEP monitoring and specific training for a neurophysiologist in the interpretation of SSEP signals.

In attempt to resolve this problem, the investigators has been involved in developing an automated SSEP device (EPAD®, SafeOp Surgical, Hunt Valley, MD; FDA approved). The automated EPAD1.0 SSEP device the investigators are currently utilizing is miniaturized and incorporates a proprietary technology utilizing non-invasive electrode patches (rather than needle electrodes) and is based on an automated algorithm derived from real-time SSEP monitoring of over 100,000 surgical procedures. The investigators was the first to evaluate the clinical utility of this automated SSEP device in cardiac surgical and total shoulder arthroplasty patients. These pilot studies found that automated SSEP monitoring can be performed readily in a busy cardiac operating room, as well as in orthopedic surgery. The raw signal quality is reliable and comparable to the conventional SSEP machine. These results indicate that this device can eliminate the practical challenges of performing SSEP monitoring and confirmed its feasibility for routine use. The initial experience has enabled further development that has incorporated software updates based on off-line data-reiteration. This has also allowed progressive refinement of the automated analysis algorithm based on this recently acquired intraoperative SSEP data to progressively optimize the software for improved signal acquisition, enhanced artifact rejection and electrocautery suppression.

METHOD Study Design This will be a prospective cohort study aiming in assessing the ability of a novel automated EMG/SSEP device (EPAD® 2.0) to detect intraoperative spinal nerve root injury in patients undergoing spine procedures. All protocol procedures will be undertaken; however, as this is the first clinical trial of EPAD® 2.0, the initial series of up to 30 patients will be used for feasibility anticipating some possible minor software revisions and minor equipment modifications. Additionally, data obtained from this initial series of patients may be utilized to iteratively refine the data collection and analysis algorithms.

Standard Procedure After obtaining preoperative written consent, a brief neurological exam will be conducted. As is conventional, anesthesia will be induced using opioid/propofol and will be maintained with halogenated anesthetic agents and supplemented with an infusion of remifentanil at 0.01-0.2 mcg/kg/min or sufentanil at 0.15 to 0.5g/kg/hr. Muscle relaxants will only be given for intubation and no second dose will be given to enable EMG monitoring. After anesthesia induction with airway and vascular access secured, the patient will be positioned for the surgery. There is no change in routine (or standard) of care except the investigators will attach the EPAD 2.0 device to the patients. After the surgery, the patient will be extubated and transferred to PACU. In all patients, a complete neurological exam will be performed in PACU.

Study Procedure:

For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. Stimulating electrodes will be placed for stimulation of the dermatome that is at risk of injury (e.g. C5), median nerve or posterior tibal nerve. Recording surface electrodes will be placed on the cervical spine at the C2 level (C2), and the reference electrode was placed on the forehead. The pre-set stimulation frequency in the EPAD device is 4.7 Hz with a 300- microsecond pulse set at 50 to 70 mA and the signal averaging set at 300 cycles. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. The EPAD device automatically established the baselines.

For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. The underlying skin will be prepared with 3M EKG skin abrasive tape (3M red dot 2236) to reduce the skin impedance. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored. The EMG monitoring can provide three main functions in spine surgery, which includes free-run EMG for detecting mechanical irritation to nerve root, triggered EMG for nerve root identification and pedicle screw placement assessment. All three EMG functions will be evaluated in this study.

Short Summary of Study Protocol:

  1. Written informed consent
  2. Focused neurological exam preoperatively
  3. Placement of surface electrodes in OR
  4. Monitoring during the spine procedure to determine the agreement of EPAD® 2.0 with the conventional intraoperative neurophysiological monitoring.
  5. Postoperative focused neurological exam in PACU postoperatively by blinded observer
  6. Data analysis/interpretation/presentation/publication
02

Conditions studied

  • Spine Disease
  • Neurological Disorder

Keywords

  • Spine surgery
  • Neuromonitoring
  • Evoked potential
  • electromyography
  • neurological injury
03

In context

Spinal Diseases

270 studies on the registry are indexed under Spinal Diseases; 54 are open to participants now.

This study's planned enrollment of 30 is below the median of 108 across 89 observational studies indexed under Spinal Diseases.

Browse Spinal Diseases studies →

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 327 studies on the registry; 132 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Study Participants: 30 patients who are scheduled to have spine surgery in LHSC.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (age>18 years old)
  • Scheduled to have either cervical or lumbosacral spine surgery. We include all patients who will undergo either single or multiple instrumented or non-instrumented decompression/fusion with either allograft or autograft bone with a preoperative diagnosis of cervical stenosis, radiculopathy, herniated nucleus pulposus, junctional stenosis, or non-union from prior surgery.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years old
  • BMI>40
  • Unable to perform preoperative neurological examination such as the language barrier
  • Fluctuating neurological signs/symptoms (eg. recent CVA, peripheral neuropathy, etc)
  • Unable to obtain informed consent
  • Contraindication to EP monitoring - skin burns or trauma at EP electrode sites
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Automated EMG/SSEP monitored

    In this study, all patients will be monitored for SSEP and EMG. For SSEP monitoring, surface adhesive electrodes will be used for both stimulation and recording. After an automatic impedance check, the baseline subcortical SSEP will be established at the beginning of each case, and the amplitude and latency of the waveforms will be measured. For EMG monitoring, 6 Surface electrodes will be attached to the same muscle groups of the conventional intraoperative neurophysiological monitoring machine. In each case, the Compound Muscle Action Potentials (CMAPs) of each muscle group will be monitored. As this is an observational study, no intervention is planned.

06

What researchers measure

Primary outcomes

  1. The feasibility of using EPAD 2.0 automated device to successfully monitor the patients in spine surgery.

    The feasibility is determined by the percentage of patients being successfully monitored in spine surgery using the EPAD 2.0 automated device (i.e. \[number of patients being successfully monitored/ total number of patients being recruited\]\*100).

    Time frame: Intraoperative

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ghobrial GM, Williams KA Jr, Arnold P, Fehlings M, Harrop JS. Iatrogenic neurologic deficit after lumbar spine surgery: A review. Clin Neurol Neurosurg. 2015 Dec;139:76-80. doi: 10.1016/j.clineuro.2015.08.022. Epub 2015 Sep 1. PubMed 26386902 ↗
  • Jimenez JC, Sani S, Braverman B, Deutsch H, Ratliff JK. Palsies of the fifth cervical nerve root after cervical decompression: prevention using continuous intraoperative electromyography monitoring. J Neurosurg Spine. 2005 Aug;3(2):92-7. doi: 10.3171/spi.2005.3.2.0092. PubMed 16370297 ↗
  • Sasai K, Saito T, Akagi S, Kato I, Ohnari H, Iida H. Preventing C5 palsy after laminoplasty. Spine (Phila Pa 1976). 2003 Sep 1;28(17):1972-7. doi: 10.1097/01.BRS.0000083237.94535.46. PubMed 12973145 ↗
  • Fan D, Schwartz DM, Vaccaro AR, Hilibrand AS, Albert TJ. Intraoperative neurophysiologic detection of iatrogenic C5 nerve root injury during laminectomy for cervical compression myelopathy. Spine (Phila Pa 1976). 2002 Nov 15;27(22):2499-502. doi: 10.1097/00007632-200211150-00014. PubMed 12435981 ↗
  • Fehlings MG, Brodke DS, Norvell DC, Dettori JR. The evidence for intraoperative neurophysiological monitoring in spine surgery: does it make a difference? Spine (Phila Pa 1976). 2010 Apr 20;35(9 Suppl):S37-46. doi: 10.1097/BRS.0b013e3181d8338e. PubMed 20407350 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2019; primary completion for Jun 2021, 23 months later.

Of 45 observational studies under Spinal Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 96. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2019
First posted
Feb 20, 2019
StartEst.
Jul 2019
Primary completionEst.
Jun 2021
CompletionEst.
Jun 2021
Last update
Mar 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03848377
Responsible party
Jason Chui (Principal Investigator, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Feb 20, 2019
Start date
Jul 2019 (estimated)
Primary completion
Jun 2021 (estimated)
Completion
Jun 2021 (estimated)
Last update
Mar 6, 2019

Study contacts

Jason Chui, MBChB
Contact
jason.chui@lhsc.on.ca
5196858500 ext. 35625
Jason Chui, MBChB
principal investigator · University of Western Ontario, Canada

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion